SEC Form 4 · accession 0001213900-17-007139
DelMar Pharmaceuticals, Inc. · DMPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Bacha
Officer — CEO · Director
Period of report
Jun 30, 2017
Accepted (ET)
Jul 5, 2017 · 2:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001498382
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 30, 2017 | J | 176 | $3.20 | A | 53,521 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.